Anavex Life Sciences Corp (AVXL)

[XenaLives]

The current discussion of patent protection is absurd.

Pharma routinely engages in "evergreening" of ip protection of drugs.

“Typically, when you evergreen something, you are not looking at any significant therapeutic advantage. You are looking at a company’s economic advantage,” says Dr. Joel Lexchin, a professor in the School of Health Policy and Management at York University in Toronto, Ontario.

“The response from the brand side is that they are trying to protect their markets so they can further invest in R&D [research and development]. And even if they make a modification to a drug, doctors are still quite able to prescribe the generic version of the older product. Having said that, the brand-name companies put an awful lot of money into marketing the newer version, and that marketing is designed to affect what doctors do.”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680578/

Missling has followed this practice and Anavex is covered six ways from Sunday. Some of the older patents seem to be routine CYA at this point, but many use ground breaking science in the treatment of CNS disease.

https://patents.justia.com/assignee/anavex-life-sciences-corp